ASH Highlights PDUFA Dates for Subcutaneous Istuximab in Myeloma, CAR T-Cell Therapy for AML/ALL/MDS
The FDA set an April 23, 2026 PDUFA date for subcutaneous isatuximab in relapsed/refractory multiple myeloma, following positive phase 3 trial results.
Read More